Loading
A phase 1 trial of Alcestobart run by Nanjing Leads Biolabs Co.,Ltd, completed.
A Study to Assess LBL-007 in Combination With Toripalimab and Axitinib Tablets Subjects With Advanced Melanoma is a phase 1 interventional study registered as NCT04640545 by Nanjing Leads Biolabs Co.,Ltd, with 79 participants enrolled, started 2020-05-12. Conditions recorded: Advanced Melanoma. Interventions recorded: LBL-007, Toripalimab and Axitinib Tablets.
Shares Alcestobart, Nanjing Leads Biolabs and the tag pipeline.
Shares Alcestobart, Nanjing Leads Biolabs and the tag pipeline.
Shares Alcestobart, Nanjing Leads Biolabs and the tag pipeline.
Shares Alcestobart, Nanjing Leads Biolabs and the tag pipeline.
Shares Alcestobart, Nanjing Leads Biolabs and the tag pipeline.
Shares Alcestobart, Nanjing Leads Biolabs and the tag pipeline.
Shares Nanjing Leads Biolabs, Melanoma and the tag pipeline.
Shares Nanjing Leads Biolabs and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/